Inhibition of Pathogen Adhesion by Bacterial Outer Membrane‐Coated Nanoparticles

Zhang, Yue; Chen, Yijie; Lo, Christopher; Zhuang, Jia; Angsantikul, Pavimol; Zhang, Qiangzhe; Wei, Xiaoli; Zhou, Zhidong; Obonyo, Marygorret; Fang, Ronnie H.; Gao, Weiwei; Zhang, Liangfang

doi:10.1002/ange.201906280

Cited by 10 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, challenges and opportunities coexist in this field. Many alternative membrane options are under investigation, such as cancer cells [ 66 , 87 ], bacteria [ 89 , 90 ] and even hybrid cell membrane vesicles [ 89 , 126 ]. For example, Gu et al successfully fabricated “Nano-Ag@erythrosome” nanocomplexs by fusing red blood cell membranes and cancer cell membranes [ 127 ].…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders

Zhu

et al. 2021

Molecules

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, causing approximately 17.9 million deaths annually, an estimated 31% of all deaths, according to the WHO. CVDs are essentially rooted in atherosclerosis and are clinically classified into coronary heart disease, stroke and peripheral vascular disorders. Current clinical interventions include early diagnosis, the insertion of stents, and long-term preventive therapy. However, clinical diagnostic and therapeutic tools are subject to a number of limitations including, but not limited to, potential toxicity induced by contrast agents and unexpected bleeding caused by anti-platelet drugs. Nanomedicine has achieved great advancements in biomedical area. Among them, cell membrane coated nanoparticles, denoted as CMCNPs, have acquired enormous expectations due to their biomimetic properties. Such membrane coating technology not only helps avoid immune clearance, but also endows nanoparticles with diverse cellular and functional mimicry. In this review, we will describe the superiorities of CMCNPs in treating cardiovascular diseases and their potentials in optimizing current clinical managements.

show abstract

Section: Conclusion and Prospectsmentioning

confidence: 99%

Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders

Zhu

et al. 2021

Molecules

View full text Add to dashboard Cite

show abstract

“…Particularly, RBC membrane-coated nanoparticles were effective in neutralizing the pore-forming toxin (PFT) staphylococcal alpha-hemolysin (αtoxin), acting as a toxin-absorbing nanosponge on account of the binding properties of PFT to their natural membrane substrates [126]. Further studies using nanodecoys coated with bacterial outer membranes of the pathogenic bacteria using H. pylori have been shown to act as anti-adhesion agents competitively binding at the mmembrane-bindingsites required for pathogen interaction and virulence [127]. In addition, cell membrane-coated nanoparticles can be loaded with antigens, toxoids or other immunostimulatory factors [124], as biomimetic toxoid nanovaccines for effective vaccination strategies.…”

Section: Bacterial Infectionsmentioning

confidence: 99%

Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination

Pereira-Silva

Chauhan

Shin

et al. 2021

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction : Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a particular coronavirus strain responsible for the coronavirus disease 2019 (COVID-19), accounting for more than 3.1 million deaths worldwide. Several health-related strategies have been successfully developed to contain the rapidly-spreading virus across the globe, toward reduction of both disease burden and infection rates. Particularly, attention has been focused on either the development of novel drugs and vaccines, or by adapting already-existing drugs for COVID-19 treatment, mobilizing huge efforts to block disease progression and to overcome the shortage of effective measures available at this point. Areas covered : This perspective covers the breakthrough of multifunctional biomimetic cell membrane-based nanoparticles as next-generation nanosystems for cutting-edge COVID-19 therapeutics and vaccination, specifically cell membrane-derived nanovesicles and cell membrane-coated nanoparticles, both tailorable cell membrane-based nanosystems enriched with the surface repertoire of native cell membranes, toward maximized biointerfacing, immune evasion, cell targeting and cell-mimicking properties. Expert opinion : Nano-based approaches have received widespread interest regarding enhanced antigen delivery, prolonged blood circulation half-life and controlled release of drugs. Cell membrane-based nanoparticles comprise interesting antiviral multifunctional nanoplatforms for blocking SARS-CoV-2 binding to host cells, reducing inflammation through cytokine neutralization and improving drug delivery toward COVID-19 treatment.

show abstract

“…With the development of biomimetic nanotechnology in modern medicine, other types of source cells can be rationally selected to decorate NPs, according to specificity of different diseases. Coating bacterial outer membrane derived from Helicobacter pylori onto surface of PLGA NPs resulted in bacterium-mimicking NPs (termed OM-NPs); the OM-NPs preserved adhesive capability toward gastric epithelial cells and thus compete with source bacteria for binding to the host cells [ 116 ]. This bacteriummimicking nanomedicine might be an alternative therapeutic for antibacterial applications because it may alleviate resistance development.…”

Section: Rationality Of Nanoplatforms In Sepsis Managementmentioning

confidence: 99%

Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis

et al. 2021

View full text Add to dashboard Cite

Sepsis, a highly life-threatening organ dysfunction caused by uncontrollable immune responses to infection, is a leading contributor to mortality in intensive care units. Sepsis-related deaths have been reported to account for 19.7% of all global deaths. However, no effective and specific therapeutic for clinical sepsis management is available due to the complex pathogenesis. Concurrently eliminating infections and restoring immune homeostasis are regarded as the core strategies to manage sepsis. Sophisticated nanoplatforms guided by supramolecular and medicinal chemistry, targeting infection and/or imbalanced immune responses, have emerged as potent tools to combat sepsis by supporting more accurate diagnosis and precision treatment. Nanoplatforms can overcome the barriers faced by clinical strategies, including delayed diagnosis, drug resistance and incapacity to manage immune disorders. Here, we present a comprehensive review highlighting the pathogenetic characteristics of sepsis and future therapeutic concepts, summarizing the progress of these well-designed nanoplatforms in sepsis management and discussing the ongoing challenges and perspectives regarding future potential therapies. Based on these state-of-the-art studies, this review will advance multidisciplinary collaboration and drive clinical translation to remedy sepsis."Image missing"

show abstract

Inhibition of Pathogen Adhesion by Bacterial Outer Membrane‐Coated Nanoparticles

Cited by 10 publications

References 41 publications

Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders

Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders

Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination

Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis

Contact Info

Product

Resources

About